{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:40:10Z","timestamp":1746160810327,"version":"3.40.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.taap.2014.03.010","type":"journal-article","created":{"date-parts":[[2014,3,23]],"date-time":"2014-03-23T11:17:29Z","timestamp":1395573449000},"page":"209-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Model-based analysis of thromboxane B2 and prostaglandin E2 as biomarkers in the safety evaluation of naproxen"],"prefix":"10.1016","volume":"278","author":[{"given":"Tarjinder","family":"Sahota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meindert","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2014.03.010_bb0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pharmtox-011112-140248","article-title":"Systems pharmacology to predict drug toxicity: integration across levels of biological organization","volume":"53","author":"Bai","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2014.03.010_bb0010","article-title":"Systems pharmacology modeling: an approach to improving drug safety","author":"Bai","year":"2013","journal-title":"Biopharm. Drug Dispos"},{"key":"10.1016\/j.taap.2014.03.010_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/wsbm.114","article-title":"Role of systems pharmacology in understanding drug adverse events","volume":"3","author":"Berger","year":"2011","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.taap.2014.03.010_bb0020","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2014.03.010_bb0025","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2014.03.010_bb0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/jpet.107.122283","article-title":"Human pharmacology of naproxen sodium","volume":"322","author":"Capone","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2014.03.010_bb0035","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bcp.12082","article-title":"Identifying the translational gap in the evaluation of drug-induced QTc-interval prolongation","volume":"76","author":"Chain","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2014.03.010_bb0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.taap.2014.03.010_bb0045","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s11095-005-5882-3","article-title":"Mechanism-based pharmacokinetic\u2013pharmacodynamic modeling\u2014a new classification of biomarkers","volume":"22","author":"Danhof","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2014.03.010_bb0050","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2008.01.007","article-title":"Mechanism-based pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) modeling in translational drug research","volume":"29","author":"Danhof","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"year":"2012","series-title":"A Language and Environment for Statistical Computing","author":"Development Core Team","key":"10.1016\/j.taap.2014.03.010_bb0170"},{"key":"10.1016\/j.taap.2014.03.010_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2007.05.007","article-title":"COX-2 in play at the AHA and the FDA","volume":"28","author":"Fitzgerald","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2014.03.010_bb0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1191\/0960327105ht517oa","article-title":"Evidence-based toxicology: a comprehensive framework for causation","volume":"24","author":"Guzelian","year":"2005","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.taap.2014.03.010_bb0065","doi-asserted-by":"crossref","first-page":"e1001482","DOI":"10.1371\/journal.pmed.1001482","article-title":"Progress in using systematic reviews of animal studies to improve translational research","volume":"10","author":"Hooijmans","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.taap.2014.03.010_bb0070","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2014.03.010_bb0075","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/rheumatology\/keh627","article-title":"Pharmacokinetic\u2013pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors","volume":"44","author":"Huntjens","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.taap.2014.03.010_bb0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.bjp.0706737","article-title":"Correlation between in vitro and in vivo concentration\u2013effect relationships of naproxen in rats and healthy volunteers","volume":"148","author":"Huntjens","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2014.03.010_bb0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0022-3565(24)29528-8","article-title":"Pharmacokinetic\/pharmacodynamic modeling of antipyretic and anti-inflammatory effects of naproxen in the rat","volume":"297","author":"Josa","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2014.03.010_bb0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2014.03.010_bb0095","doi-asserted-by":"crossref","first-page":"e7824","DOI":"10.1371\/journal.pone.0007824","article-title":"Survey of the quality of experimental design, statistical analysis and reporting of research using animals","volume":"4","author":"Kilkenny","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2014.03.010_bb0100","doi-asserted-by":"crossref","first-page":"320","DOI":"10.14573\/altex.2007.4.320","article-title":"Animal experiments scrutinised: systematic reviews demonstrate poor human clinical and toxicological utility","volume":"24","author":"Knight","year":"2007","journal-title":"ALTEX"},{"key":"10.1016\/j.taap.2014.03.010_bb0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2014.03.010_bb0110","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/hc4401.100078","article-title":"Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib","volume":"104","author":"Konstam","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2014.03.010_bb0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10928-012-9240-x","article-title":"Evaluation of IPPSE, an alternative method for sequential population PKPD analysis","volume":"39","author":"Lacroix","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.taap.2014.03.010_bb0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.gastro.2008.05.030","article-title":"Gastric mucosal defense and cytoprotection: bench to bedside","volume":"135","author":"Laine","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.taap.2014.03.010_bb0125","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.taap.2014.03.010_bb0130","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.taap.2014.03.010_bb0135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.taap.2014.03.010_bb0145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tips.2009.12.001","article-title":"Gender differences in drug toxicity","volume":"31","author":"Nicolson","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2014.03.010_bb0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/0976-500X.81895","article-title":"Toxicological screening","volume":"2","author":"Parasuraman","year":"2011","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.taap.2014.03.010_bb0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/bmj.39048.407928.BE","article-title":"Comparison of treatment effects between animal experiments and clinical trials: systematic review","volume":"334","author":"Perel","year":"2007","journal-title":"Br. Med. J."},{"key":"10.1016\/j.taap.2014.03.010_bb0165","series-title":"Textbook of Adverse Drug Reactions","first-page":"18","article-title":"Mechanisms of adverse drug reactions","author":"Rawlins","year":"1991"},{"key":"10.1016\/j.taap.2014.03.010_bb0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/cpt1974153261","article-title":"Nonlinear plasma level response to high doses of naproxen","volume":"15","author":"Runkel","year":"1974","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2014.03.010_bb0185","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0378-4347(00)83116-3","article-title":"High-performance liquid chromatographic determination of ketoprofen and naproxen in rat plasma","volume":"431","author":"Satterwhite","year":"1988","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.taap.2014.03.010_bb0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/jmcc.2001.1484","article-title":"Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction","volume":"34","author":"Scheuren","year":"2002","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.taap.2014.03.010_bb0195","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1254\/jjp.28.569","article-title":"Strain differences in aspirin-induced gastric ulceration in rats","volume":"28","author":"Urushidani","year":"1978","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.taap.2014.03.010_bb0200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14573\/altex.2011.1.017","article-title":"Current standing and future prospects for the technologies proposed to transform toxicity testing in the 21st century","volume":"28","author":"van Vliet","year":"2011","journal-title":"ALTEX"},{"key":"10.1016\/j.taap.2014.03.010_bb0205","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat. New Biol."},{"key":"10.1016\/j.taap.2014.03.010_bb0210","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","article-title":"Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance","volume":"30","author":"Zhang","year":"2003","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.taap.2014.03.010_bb0215","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/B:JOPA.0000012999.36063.4e","article-title":"Simultaneous vs. sequential analysis for population PK\/PD data II: robustness of methods","volume":"30","author":"Zhang","year":"2003","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X14000969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X14000969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:05:46Z","timestamp":1746158746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X14000969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0041008X14000969"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2014.03.010","relation":{},"ISSN":["0041-008X"],"issn-type":[{"type":"print","value":"0041-008X"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Model-based analysis of thromboxane B2 and prostaglandin E2 as biomarkers in the safety evaluation of naproxen","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2014.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}